# Real-World Assessment of Therapeutic Strategies and Survival Outcomes Following First-Line Tislelizumab Therapy in Advanced Non-Small Cell Lung Cancer

> **NCT06962449** · — · ENROLLING_BY_INVITATION · sponsor: **Shanghai Chest Hospital** · enrollment: 500 (estimated)

## Conditions studied

- Non-Small-Cell Lung Cancer
- Non-Small-Cell Lung Cancer Stage IV

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06962449
- **Lead sponsor:** Shanghai Chest Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2024-08-16
- **Primary completion:** 2025-06-30
- **Final completion:** 2026-12-31
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2025-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06962449

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06962449, "Real-World Assessment of Therapeutic Strategies and Survival Outcomes Following First-Line Tislelizumab Therapy in Advanced Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06962449. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*